Diastolic dysfunction: Potential new diagnostics and therapies

Circulation Journal

Volumn 79, Issue 3, 2015, Pages 470-477

  Jeong, Euy Myoung ^a   Dudley, Samuel C ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Diastolic dysfunction; Heart failure; Myofilament Ca2+ sensitivity; Oxidative stress; Ventricular relaxation

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALDOSTERONE ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; CONNECTIN; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIGOXIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; MYOSIN BINDING PROTEIN C; NEBIVOLOL; PERINDOPRIL; RAMIPRIL; RANOLAZINE; SILDENAFIL; SPIRONOLACTONE; TETRAHYDROBIOPTERIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; COLOR ULTRASOUND FLOWMETRY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TISSUE DOPPLER IMAGING; ANIMAL; CLINICAL TRIAL (TOPIC); DIASTOLE; HEART STROKE VOLUME; PATHOPHYSIOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIASTOLE; HEART FAILURE; HUMANS; OXIDATIVE STRESS; STROKE VOLUME;

EID: 84923395725     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0064     Document Type: Article

References (67)

1. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol 1984; 54: 778–782.
2. LeWinter MM, Meyer M. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it’s not one thing it’s another. Circ Heart Fail 2013; 6: 1112–1115.
3. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202.
4. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart Disease and Stroke Statistics 2010 Update: A report from the American Heart Association. Circulation 2010; 121: e46–e215, doi:10.1161/CIRCULATIONAHA.109.192667.
5. Ministry of Health, Labour and Welfare. Summary of vital statistics 2005. http://www.mhlw.go.jp/english/database/db-hw/populate/index.html (accessed January 18, 2015).
6. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259.
7. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: A scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544–2565.
8. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study. Lancet 2003; 361: 1843–1848.
9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–e239, doi:10.1016/j.jacc.2013.05.019.
10. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res 2000; 45: 813–825.
11. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004; 94: 1533–1542.
12. Little WC, Zile MR. HFpEF: Cardiovascular abnormalities not just comorbidities. Circ Heart Fail 2012; 5: 669–671.
13. Halley CM, Houghtaling PL, Khalil MK, Thomas JD, Jaber WA. Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med 2011; 171: 1082–1087.
14. Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: A mechanistic appraisal. Circulation 2012; 126: 2353–2362.
15. Maharaj R. Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia. J Saudi Heart Assoc 2012; 24: 99–121.
16. Maack C, Bohm M. Targeting mitochondrial oxidative stress in heart failure: Throttling the afterburner. J Am Coll Cardiol 2011; 58: 83–86.
17. Jeong EM, Dudley SC Jr. New diagnostic and therapeutic possibilities for diastolic heart failure. RI Med J 2014; 97: 35–37.
18. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: Causal mechanisms and treatment. Circulation 2002; 105: 1503–1508.
19. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113: 305–315.
20. Shannon TR, Lew WY. Diastolic release of calcium from the sarcoplasmic reticulum: A potential target for treating triggered arrhythmias and heart failure. J Am Coll Cardiol 2009; 53: 2006–2008.
21. Gonzalez DR, Treuer AV, Castellanos J, Dulce RA, Hare JM. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem 2010; 285: 28938–28945.
22. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008; 133: 462–474.
23. Qin F, Siwik DA, Lancel S, Zhang J, Kuster GM, Luptak I, et al. Hydrogen peroxide-mediated SERCA cysteine 674 oxidation contributes to impaired cardiac myocyte relaxation in senescent mouse heart. J Am Heart Assoc 2013; 2: e000184, doi:10.1161/JAHA.113.000184.
24. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113: 1966–1973.
25. Fukuda N, Wu Y, Nair P, Granzier HL. Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoformdependent manner. J Gen Physiol 2005; 125: 257–271.
26. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009; 104: 87–94.
27. Reed AL, Tanaka A, Sorescu D, Liu H, Jeong EM, Sturdy M, et al. Diastolic dysfunction is associated with cardiac fibrosis in the senescence- accelerated mouse. Am J Physiol Heart Circ Physiol 2011; 301: H824–H831.
28. Chiao YA, Ramirez TA, Zamilpa R, Okoronkwo SM, Dai Q, Zhang J, et al. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res 2012; 96: 444–455.
29. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888–895.
30. Ciurzynski M, Bienias P, Irzyk K, Kostrubiec M, Szewczyk A, Demkow U, et al. Heart diastolic dysfunction in patients with systemic sclerosis. Arch Med Sci 2014; 10: 445–454.
31. Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska- Plaksej J, Bednarek-Tupikowska G, Mazurek W. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: Relationship to cardiac function. Int J Obes (Lond) 2008; 32: 763–771.
32. Fraysse B, Weinberger F, Bardswell SC, Cuello F, Vignier N, Geertz B, et al. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol 2012; 52: 1299–1307.
33. Barefield D, Sadayappan S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 2010; 48: 866–875.
34. Jeong EM, Monasky MM, Gu L, Taglieri DM, Patel BG, Liu H, et al. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol 2013; 56: 44–54.
35. Oh JK, Park SJ, Nagueh SF. Established and novel clinical applications of diastolic function assessment by echocardiography. Circ Cardiovasc Imaging 2011; 4: 444–455.
36. Asrar ul Haq M, Mutha V, Lin T, Profitis K, Tuer Z, Lim K, et al. Left ventricular torsional dynamics post exercise for LV diastolic function assessment. Cardiovasc Ultrasound 2014; 12: 8.
37. Daneshvar D, Wei J, Tolstrup K, Thomson LE, Shufelt C, Merz CN. Diastolic dysfunction: Improved understanding using emerging imaging techniques. Am Heart J 2010; 160: 394–404.
38. Garcia MJ, Palac RT, Malenka DJ, Terrell P, Plehn JF. Color M-mode Doppler flow propagation velocity is a relatively preloadindependent index of left ventricular filling. J Am Soc Echocardiogr 1999; 12: 129–137.
39. Dusch MN, Thadani SR, Dhillon GS, Hope MD. Diastolic function assessed by cardiac MRI using longitudinal left ventricular fractional shortening. Clin Imaging 2014; 38: 666–668.
40. Vorovich E, French B, Ky B, Goldberg L, Fang JC, Sweitzer NK, et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: A recurrent event analysis. J Card Fail 2014; 20: 569–576.
41. Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL, et al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol 2012; 52: 154–164.
42. Jeong EM, Brahmanandam V, Raicu M, Lee SY, Chung JH, Rutledge C, et al. Plasma myosin binding protein-C fragments and S-glutathionylation in diastolic heart failure (abstract). Circulation 2012; 126: A11366.
43. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–2345.
44. Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, et al. The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008; 94: 573–580.
45. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, et al. Diastolic dysfunction in heart failure with preserved systolic function: Need for objective evidence: Results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007; 49: 687–694.
46. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456–2467.
47. Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184–192.
48. Flather MD, Shibata MC, Coats AJ, van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–225.
49. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–2261.
50. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228–1233.
51. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781–791.
52. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383–1392.
53. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–533.
54. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 2010; 121: 519–528.
55. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2013; 309: 1268–1277.
56. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012; 110: 841–850.
57. Zhang XQ, Yamada S, Barry WH. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia. J Cardiovasc Pharmacol 2008; 51: 443–449.
58. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALIDHF proof-of-concept study. JACC Heart Fail 2013; 1: 115–122.
59. Smith TW, Balligand JL, Kaye DM, Wiviott SD, Simmons WW, Han X, et al. The role of the NO pathway in the control of cardiac function. J Card Fail 1996; 2: S141–S147.
60. Carnicer R, Hale AB, Suffredini S, Liu X, Reilly S, Zhang MH, et al. Cardiomyocyte GTP cyclohydrolase 1 and tetrahydrobiopterin increase NOS1 activity and accelerate myocardial relaxation. Circ Res 2012; 111: 718–727.
61. Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, Ungvari Z, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: In vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2010; 299: H985–H994.
62. Xia N, Daiber A, Habermeier A, Closs EI, Thum T, Spanier G, et al. Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J Pharmacol Exp Ther 2010; 335: 149–154.
63. Bartholome K, Lutz P, Bickel H. Determination of phenylalanine hydroxylase activity in patients with phenylketonuria and hyperphenylalaninemia. Pediatr Res 1975; 9: 899–903.
64. Chung J, Jeong EM, Go Y, Gladstein S, Farzaneh-Far A, Lewandowski ED, et al. Mitochondria-targeted antioxidant ameliorates diet-induced diabetes and diastolic dysfunction (abstract). J Am Coll Cardiol 2015; 61: E597.
65. Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z, et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest 2013; 123: 1262–1274.
66. He Q, Harris N, Ren J, Han X. Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes. Oxid Med Cell Longev 2014; 2014: 654198.
67. Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS. Mitochondrial oxidative stress in aging and healthspan. Longev Healthspan 2014; 3: 6.